PMID- 20562701
OWN - NLM
STAT- MEDLINE
DCOM- 20100817
LR  - 20100721
IS  - 1530-0293 (Electronic)
IS  - 0090-3493 (Linking)
VI  - 38
IP  - 8
DP  - 2010 Aug
TI  - Bone marrow-derived mononuclear cell therapy in experimental pulmonary and 
      extrapulmonary acute lung injury.
PG  - 1733-41
LID - 10.1097/CCM.0b013e3181e796d2 [doi]
AB  - OBJECTIVE: To hypothesize that bone marrow-derived mononuclear cell (BMDMC) 
      therapy might act differently on lung and distal organs in models of pulmonary or 
      extrapulmonary acute lung injury with similar mechanical compromises. The 
      pathophysiology of acute lung injury differs according to the type of primary 
      insult. DESIGN: Prospective, randomized, controlled, experimental study. SETTING: 
      University research laboratory. MEASUREMENTS AND MAIN RESULTS: In control 
      animals, sterile saline solution was intratracheally (0.05 mL) or 
      intraperitoneally (0.5 mL) injected. Acute lung injury animals received 
      Escherichia coli lipopolysaccharide intratracheally (40 microg, ALIp) or 
      intraperitoneally (400 microg, ALIexp). Six hours after lipopolysaccharide 
      administration, ALIp and ALIexp animals were further randomized into subgroups 
      receiving saline (0.05 mL) or BMDMC (2 x 10) intravenously. On day 7, BMDMC led 
      to the following: 1) increase in survival rate; 2) reduction in static lung 
      elastance, alveolar collapse, and bronchoalveolar lavage fluid cellularity 
      (higher in ALIexp than ALIp); 3) decrease in collagen fiber content, cell 
      apoptosis in lung, kidney, and liver, levels of interleukin-6, KC (murine 
      interleukin-8 homolog), and interleukin-10 in bronchoalveolar lavage fluid, and 
      messenger RNA expression of insulin-like growth factor, platelet-derived growth 
      factor, and transforming growth factor-beta in both groups, as well as repair of 
      basement membrane, epithelium and endothelium, regardless of acute lung injury 
      etiology; 4) increase in vascular endothelial growth factor levels in 
      bronchoalveolar lavage fluid and messenger RNA expression in lung tissue in both 
      acute lung injury groups; and 5) increase in number of green fluorescent 
      protein-positive cells in lung, kidney, and liver in ALIexp. CONCLUSIONS: BMDMC 
      therapy was effective at modulating the inflammatory and fibrogenic processes in 
      both acute lung injury models; however, survival and lung mechanics and histology 
      improved more in ALIexp. These changes may be attributed to paracrine effects 
      balancing pro- and anti-inflammatory cytokines and growth factors, because a 
      small degree of pulmonary BMDMC engraftment was observed.
FAU - Araujo, Indianara M
AU  - Araujo IM
AD  - Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of 
      Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
FAU - Abreu, Soraia C
AU  - Abreu SC
FAU - Maron-Gutierrez, Tatiana
AU  - Maron-Gutierrez T
FAU - Cruz, Fernanda
AU  - Cruz F
FAU - Fujisaki, Livia
AU  - Fujisaki L
FAU - Carreira, Humberto Jr
AU  - Carreira H Jr
FAU - Ornellas, Felipe
AU  - Ornellas F
FAU - Ornellas, Debora
AU  - Ornellas D
FAU - Vieira-de-Abreu, Adriana
AU  - Vieira-de-Abreu A
FAU - Castro-Faria-Neto, Hugo C
AU  - Castro-Faria-Neto HC
FAU - Muxfeldt Ab'Saber, Alexandre
AU  - Muxfeldt Ab'Saber A
FAU - Teodoro, Walcy R
AU  - Teodoro WR
FAU - Diaz, Bruno L
AU  - Diaz BL
FAU - Peres Dacosta, Carlos
AU  - Peres Dacosta C
FAU - Capelozzi, Vera L
AU  - Capelozzi VL
FAU - Pelosi, Paolo
AU  - Pelosi P
FAU - Morales, Marcelo M
AU  - Morales MM
FAU - Rocco, Patricia R M
AU  - Rocco PR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
RN  - 0 (Cytokines)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Platelet-Derived Growth Factor)
RN  - 0 (RNA, Messenger)
RN  - 0 (Transforming Growth Factor beta)
RN  - EC 3.4.22.- (Caspase 3)
SB  - IM
MH  - Acute Lung Injury/chemically induced/mortality/physiopathology/*therapy
MH  - Animals
MH  - Apoptosis/*physiology
MH  - Bone Marrow Transplantation/*methods
MH  - Bronchoalveolar Lavage Fluid/cytology
MH  - Caspase 3/metabolism
MH  - Cytokines/*metabolism
MH  - Disease Models, Animal
MH  - Escherichia coli
MH  - Female
MH  - Leukocytes, Mononuclear/transplantation
MH  - Lipopolysaccharides
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Microscopy, Confocal
MH  - Microscopy, Electron
MH  - Platelet-Derived Growth Factor/metabolism
MH  - RNA, Messenger/metabolism
MH  - Random Allocation
MH  - Reference Values
MH  - Respiratory Mechanics/*physiology
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Survival Rate
MH  - Transforming Growth Factor beta/metabolism
EDAT- 2010/06/22 06:00
MHDA- 2010/08/18 06:00
CRDT- 2010/06/22 06:00
PHST- 2010/06/22 06:00 [entrez]
PHST- 2010/06/22 06:00 [pubmed]
PHST- 2010/08/18 06:00 [medline]
AID - 10.1097/CCM.0b013e3181e796d2 [doi]
PST - ppublish
SO  - Crit Care Med. 2010 Aug;38(8):1733-41. doi: 10.1097/CCM.0b013e3181e796d2.